Oxford Biomedica PLC/ GB00BDFBVT43 /
13/11/2024 17:29:43 | Chg. -2.00 | Volume | Bid17:30:00 | Ask17:30:00 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
422.00GBX | -0.47% | 10,706 Turnover(GBP): 45,437.7125 |
-Bid Size: - | -Ask Size: - | 335.68 mill.GBP | - | - |
GlobeNewswire
06/08
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
06/03
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GlobeNewswire
05/03
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
GlobeNewswire
23/01
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufac...
GlobeNewswire
07/01
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical ...
GlobeNewswire
03/01
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire
04/12/2023
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position...
GlobeNewswire
09/11/2023
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
20/09/2023
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed...
GlobeNewswire
20/09/2023
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
GlobeNewswire
23/03/2022
Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights